A A van de Loosdrecht, E M P Cremers, C Alhan, C Duetz, F E M In 't Hout, H A Visser-Wisselaar, D A Chitu, A Verbrugge, S M Cunha, G J Ossenkoppele, J J W M Janssen, S K Klein, E Vellenga, G A Huls, P Muus, S M C Langemeijer, G E de Greef, P A W Te Boekhorst, M H G Raaijmakers, M van Marwijk Kooy, M C Legdeur, J J Wegman, W Deenik, O de Weerdt, T M van Maanen-Lamme, P Jobse, R J W van Kampen, A Beeker, P W Wijermans, B J Biemond, B C Tanis, J W J van Esser, C G Schaar, H S Noordzij-Nooteboom, E M G Jacobs, A O de Graaf, M Jongen-Lavrencic, M J P L Stevens-Kroef, T M Westers, J H Jansen
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70...
January 31, 2024: Leukemia